Peptides DB
Research-centric peptide and protocol reference hub
NatureNovember 13, 2026

Rare GLP1R variants diminish the weight loss effect of semaglutide but not of tirzepatide

Reported by Nature. Read the original →

What the story says

The headline reports that rare variants of the GLP1 receptor diminish the weight loss effect of semaglutide, while this effect is not observed with tirzepatide.

Summarised by a model from Nature's headline and its own description of the story. We did not read the article, and this is not our reporting — the link above is.

On file here

Every number below is counted from this library's own approved studies — the ones with a page you can open and check. Counts move as papers are filed.

What the headline doesn't tell you

  • Semaglutide has 62 studies on file, 34 of them in humans, the newest published 2026.
  • Tirzepatide has 33 studies on file, 19 of them in humans, the newest published 2026.

Counted, not written: each line is a sentence filled in from the study counts above. None of it is a judgement about the story or the compound.